The invention relates to compounds of the formula I:R1 is selected from the group consisting of hydrogen, linear C1C3alkyl and fluorinated linear C1-C3alkyl；R2 is hydrogen or methyl；R3 is selected from the group consisting of hydrogen, halogen, C1-C2-alkyl, fluorinated C1-C2-alkyl, C1-C2-alkoxy and fluorinated C1-C2-alkoxy,R4 is C1-C2-alkyl or fluorinated C1-C2-alkyl；n is 0, 1 or 2,and the physiologically tolerated salts of these compounds and the N-oxides thereof.The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3receptor antagonists or dopamine D3agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.本發明係關於式I化合物：R1 係選自由氫、直線型C1-C3烷基及氟化直線型C1-C3烷基組成之群；R2 係氫或甲基；R3 係選自由氫、鹵素、C1-C2-烷基、氟化C1-C2-烷基、C1-C2-烷氧基及氟化C1-C2-烷氧基組成之群，R4 係C1-C2-烷基或氟化C1-C2-烷基；n 係0、1或2，及此等化合物之生理學上可耐受之鹽及其N-氧化物。本發明亦關於一種醫藥組合物，其包含至少一種式I化合物及/或至少一種其生理學上可耐受之酸加成鹽，且本發明進一步關於一種用於治療對多巴胺D3受體拮抗劑或多巴胺D3激動劑有利反應之疾病的方法，該方法包括對需要之個體投與有效量之至少一種式I之化合物或生理學上可耐受之酸加成鹽。
